[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-disease-ckd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-disease-ckd":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100605547","analysis-of-the-influence-of-dialysis-fluid-composition-on-vascular-calcification-in-patients-with-chronic-kidney-disease-undergoing-hemodialysis-100605547",false,"NCT07163936","Analysis of the Influence of Dialysis Fluid Composition on Vascular Calcification in Patients With Chronic Kidney Disease Undergoing Hemodialysis","CalCio-HD","Inclusion Criteria:\n\n* Adults (≥18 years old) on maintenance hemodialysis for more than 3 months\n* Clinically stable patients with a well-functioning vascular access\n* Residual urine output ≤ 250 mL\u002Fday\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy or intolerance to any component of the dialysates\n* Active malignancy or infectious\u002Finflammatory disease\n* Planned living donor kidney transplant before study completion\n* Current treatment with vitamin K antagonists (coumarins)\n* Severe hypocalcemia or poorly controlled secondary hyperparathyroidism\n* Any condition that, in the investigator's judgment, contraindicates participation or affects study compliance","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to find out if using a citrate-based dialysate with added magnesium during hemodialysis can help slow down or prevent the hardening of blood vessels (vascular calcification) in adults on long-term dialysis.\n\nThe main questions the study will try to answer are:\n\nDoes citrate-based dialysate with magnesium improve the blood's ability to prevent calcium buildup (measured by a test called T50) compared to acetate-based dialysate?\n\nDoes it modify magnesium, calcium and parathyroid hormone (PTH) levels in the blood?\n\nDoes it lower the chances of heart problems or death?\n\nResearchers will compare two groups: one will receive acetate-based dialysate, and the other will receive citrate-based dialysate with magnesium.\n\nParticipants will:\n\nReceive one of the two types of dialysate during their regular hemodialysis sessions for 12 months\n\nHave regular blood tests\n\nBe monitored for any heart problems and for overall health during the study",[26,27,28],"Vascular Calcification","Hemodialysis","Cardiovascular Disease (CKD)",[30,31,32,33,34,35,36,37],"hemodialysis","dialysate","citrate dialysate","acetate dialysate","magnesium supplementation","calcification propensity","vascular calcification","dialysate composition","NOT_YET_RECRUITING","2025-09-01",{"date":41,"type":42},"2025-09-09","ACTUAL",{"date":44,"type":20},"2025-09-03",{"date":46,"type":20},"2026-09-06",{"name":48,"class":49},"Hospital Clinic of Barcelona","OTHER"]